PMA device
PD-L1 IHC 22C3 pharmDx
Agilent Technologies, Inc. · Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS, Class III) · First FDA decision Oct 2, 2015, newest Mar 19, 2026Cancer detection and genomic testingLung cancer and lung nodules
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
20
PMA pathway
Device trials
0
Naming "PD-L1 IHC 22C3"
MAUDE reports
3
Brand "PD-L1 IHC 22C3", since 2015
PubMed studies
67
Mentioning "PD-L1 IHC 22C3"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing PD-L1 IHC 22C3 pharmDx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 20 decisions filed under this name.
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S031 · Decided Mar 19, 2026 · 234 days after receipt · Normal 180 Day Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S033 · Decided Feb 10, 2026 · 134 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S032 · Decided Feb 11, 2026 · 187 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P150013-S021, P150013-S020, P150013-S019, P150013-S018, P150013-S017, P150013-S016, P150013-S014, P150013-S012, P150013-S011, P150013-S009, P150013-S007, P150013-S006, P150013-S001, P150013
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PD-L1 IHC 22C3", any status and sponsor, newest update first.
No registered device study names "PD-L1 IHC 22C3".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PD-L1 IHC 22C3", and for the whole product code for context.
This brand
3 reports: 3 malfunction, 0 injury, 0 death
Whole product code PLS
35 reports: 34 malfunction, 1 injury, 0 death
Newest reports for this brand
- PD-L1 IHC 22C3 PHARMDXMalfunction
2916205-2021-00004 · Received Mar 16, 2021 · Event dated Feb 26, 2021
Device type: Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- PD-L1 IHC 22C3 PHARMDXMalfunction
2916205-2021-00003 · Received Mar 9, 2021 · Event dated Mar 16, 2021
Device type: Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- PD-L1 IHC 22C3 PHARMDXMalfunction
2022180-2017-00001 · Received Jan 11, 2017 · Event dated Dec 6, 2016
Device type: Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS)
Device problem as coded: Manufacturing, Packaging or Shipping Problem
Patient problem as coded: No Known Impact Or Consequence To Patient; No Code Available
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "PD-L1 IHC 22C3"[tiab]. The summary above synthesizes these.
- Comparison of PD-L1 IHC 22C3 PharmDx Combined Positive Score (CPS) in Primary Versus Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?
Surucu A, Hou T, Kuhar M, et al. · Appl Immunohistochem Mol Morphol · 2023Research Support, Non-U.S. Gov't
- Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Kalpakoff M, Hund S, Musser J, et al. · Appl Immunohistochem Mol Morphol · 2021Research Support, Non-U.S. Gov't
- Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
Vainer G, Huang L, Emancipator K, et al. · PLoS One · 2023Research Support, Non-U.S. Gov't
- Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
Gadgeel SM, Rodríguez-Abreu D, Halmos B, et al. · J Thorac Oncol · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Skov BG · Appl Immunohistochem Mol Morphol · 2021Research Support, Non-U.S. Gov't, Validation Study
- Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses.
Basu A, Chiriboga L, Narula N, et al. · J Histotechnol · 2020Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Tissue and Blood Biomarkers in Lung Cancer: A Review.
Duffy MJ, O'Byrne K · Adv Clin Chem · 2018Review
- Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
Ilié M, Ngo-Mai M, Long-Mira E, et al. · J Vis Exp · 2018Research Support, Non-U.S. Gov't, Video-Audio Media
- Whole Slide Image vs Microscope Glass Slide Performance for the Evaluation of Programmed Death-Ligand 1 (PD-L1) Expression in 14 Tumor Types Using PD-L1 IHC 22C3 pharmDx.
Adams M, Moquin D, Tabuena-Frolli S, et al. · Mod Pathol · 2025Comparative Study, Research Support, Non-U.S. Gov't
- Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
Jørgensen JT · Expert Rev Mol Diagn · 2016Editorial
- Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.
Perez J, Kerr KM, Baker B, et al. · JCO Precis Oncol · 2025Clinical Trial, Phase III, Multicenter Study
- The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinoma.
Economopoulou P, Rampias T, Spathis A, et al. · ESMO Open · 2025
Other devices of this type
Also filed under product code PLS.
- VENTANA PD-L1 (SP263) AssayVentana Medical Systems, Inc. · PMA 2023
- PD-L1 IHC 28-8 pharmDxAgilent Technologies, Inc. · PMA 2026
- VENTANA PD-L1 (SP263) CDx AssayVentana Medical Systems, Inc. · PMA 2024
- PD-L1 Ihc 28-8 PharmdxDako North America, Inc. · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.